Gene Therapy Market Opportunity, Trends, Industry Analysis Report, 2025 - 2034

Gene Therapy Market Size, Share, Trends, Industry Analysis Report: By Therapeutic Area (Autoimmune Disorders, Cardiovascular Diseases, Dermatological Disorders, Hematological Disorders, Metabolic Disorders, Muscle-Related Diseases, Oncological Disorders, and Others), Vector Type, Approach, Route of Administration, and Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) – Market Forecast 2025–2034

Published Date:Feb-2025
Pages: 154
Format: PDF
Report ID: PM1084
Base Year: 2024
Historical Data: 2020-2023

Gene Therapy Market Overview

The global gene therapy market size was valued at USD 2,251.50 million in 2024. The market is projected to grow from USD 2,657.00 million in 2025 to USD 27,250.20 million by 2034, exhibiting a CAGR of 27.1% during 2025–2034.

Gene therapy refers to modifying a person's genes in order to treat certain diseases and conditions. It covers a wide range of aspects, from development, testing, and production to the marketing and distribution of gene-based therapies. Gene therapy encompasses the modification, addition, or alteration of genes to treat genetic disorders or improve specific biological processes. The gene therapy market demand is propelled by gene delivery technology advancements, strong research pipelines, and increasing regulatory approvals. Significant investors focus their funds on developing therapies for many other conditions, including cancer and central nervous system disorders. In spite of the increasing costs of development and stringent regulations, the overall market conditions have optimism for growth.

The prevalence of genetic disorders such as Duchenne muscular dystrophy (DMD), sickle cell disease, and cystic fibrosis is rising. The CDC reports that sickle cell disease affects approximately 100,000 Americans, and the incidence of cystic fibrosis is about 1 in 3,000 newborns in the US. Increased in these disease cases drives patients and healthcare providers to seek effective treatments. Gene therapy offers a promising solution by targeting and correcting defective genes, potentially providing a cure or significantly improving patient outcomes. Therefore, the demand for gene therapy is increasing with the rising incidence of genetic disorders such as Duchenne muscular dystrophy (DMD), sickle cell disease, and cystic fibrosis.

To Understand More About this Research: Request a Free Sample Report

The gene therapy market development is driven by rising regulatory support. The US FDA has approved multiple gene therapies, including Luxturna (2017), Zolgensma (2019), and Casgevy/Lovotibeglogene autotemcel (2023) for sickle cell disease. The European Medicines Agency (EMA) has also approved Skysona (bluebird bio) for cerebral adrenoleukodystrophy. Expedited pathways such as RMAT (Regenerative Medicine Advanced Therapy) and PRIME (Priority Medicines) in the EU facilitate faster approvals, enhancing investment attractiveness and accelerating commercialization of gene therapy, thereby propelling market growth.

Gene Therapy Market Dynamics

Rising Approval and Investments in Gene Therapy Development

The launch of Akcea Therapeutics’ Tegsedi, with the approval of Novartis’ Zolgensma, upheld the global gene therapy market with substantial growth. Big pharma companies are investing heavily in gene therapy. Roche acquired Spark Therapeutics for USD 4.3 billion, whereas Pfizer is actively developing multiple gene therapy programs. Biotech companies such as Bluebird Bio and Sarepta have secured significant funding to advance their product pipelines. Venture capital funding for gene therapy startups exceeded USD 3 billion in 2023, with major deals such as ElevateBio’s USD 401 million investment. The ongoing competitive strategies adopted by market participants, as well as the wide application portfolio of the therapy, in addition to its efficacy, is leading toward rapid gene therapy market growth.

Growing Prevalence of Target Diseases

Cardiovascular diseases have become the most dominant cause of mortality and morbidity in the world for the last three decades. According to a report published by the WHO (World Health Organization), cardiovascular diseases will cause ∼23.3 million deaths by 2030. The high presence of unmet medical needs pertaining to this disease and the subsequent rise observed in patient awareness levels across the globe is boosting the demand for gene therapy as it helps find the right medication to manage cardiovascular disorders. Therefore, the growing prevalence of target diseases such as cancer, cardiovascular diseases, and others is fueling the gene therapy market expansion.

Growing Geriatric Population Base

The global geriatric population base is on the rise. Estimates published by the WHO suggest that the global base of population pertaining to the age group 65 years and above is expected to rise from 7% in 2000 to 16% in 2050. Japan and China are two of the Asian countries with the most geriatric population, with Japan’s geriatric population growing at a very rapid pace. Estimates suggest that more than 20% of the population in Japan is over the age of 65 years. Geriatric population is highly prone to diseases, such as cardiovascular and cancer, and gene therapy is a widely used therapeutic to treat these diseases or conditions. Hence, the rising geriatric population across the world boosts the gene therapy market growth.

Gene Therapy Market Segment Analysis

Gene Therapy Market Assessment by Therapeutic Area Outlook

The global gene therapy market segmentation, based on therapeutic area, has been segmented into autoimmune disorders, cardiovascular diseases, dermatological disorders, hematological disorders, metabolic disorders, muscle-related diseases, oncological disorders, and others. The oncological disorders segment accounted for around 38% of the gene therapy market share in 2024 due to the high global cancer burden (19.3 million new cases in 2020, as per WHO) and the success of CAR-T cell therapies such as Kymriah and Yescarta, which have shown significant efficacy in hematologic malignancies. Advances in gene editing and viral vector delivery further enhance precision treatment, driving the adoption of gene therapies in oncology.

Gene Therapy Market Evaluation by Vector Type Outlook

The global gene therapy market segmentation, on the basis of vector type, includes viral vectors and non-viral vectors. The viral vectors segment is expected to register a higher CAGR of 27.3% during the forecast period due to their high transduction efficiency, stable gene expression, and ability to target specific cells, making them ideal for therapies such as Luxturna and Zolgensma. Researchers and biotech companies are widely using viral vectors such as adeno-associated viruses (AAVs), lentiviruses, and retroviruses owing to their strong transduction capabilities and long-lasting gene expression. Adeno-associated viruses (AAVs), in particular, gained popularity due to their low immunogenicity and ability to target non-dividing cells, making them ideal for treating inherited disorders. Increased funding for gene-based treatments, along with successful clinical trials and regulatory approvals, contributed to the viral vectors segment growth. Additionally, advancements in vector engineering reduced toxicity and improved delivery precision, further contributing to their growth.

Gene Therapy Market Regional Analysis

By region, the study provides gene therapy market insights into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. North America dominated the gene therapy market revenue share in 2024 due to strong regulatory support, high investments in R&D, and a well-established biopharma ecosystem. The FDA has approved multiple gene therapies, including Luxturna, Zolgensma, and Casgevy, further accelerating commercialization and adoption. In 2023, the US accounted for over 65% of global gene therapy clinical trials, supported by NIH and private funding exceeding USD 10 billion. Major biotech hubs such as Boston and San Francisco house and prominent players such as Novartis, Bluebird Bio, and Sarepta are driving innovation in the market in North America. Additionally, the region benefits from advanced manufacturing infrastructure, reimbursement policies, and increasing patient access to gene therapies.

Europe holds the second largest share in the gene therapy market due to its strong regulatory frameworks, high R&D investments, and a growing number of approved therapies. The European Medicines Agency (EMA) has approved multiple gene therapies, including Skysona, Libmeldy, and Roctavian, supporting gene therapy market expansion. Countries such as Germany, France, and the UK lead in clinical trials, with government-backed initiatives such as Horizon Europe funding advanced therapies. Additionally, Europe has a well-established biopharma ecosystem, with companies such as Orchard Therapeutics and UniQure, which are driving innovation in the market. Expanding manufacturing capabilities, along with increasing adoption of value-based reimbursement models, further strengthen Europe's position in the market.

Gene Therapy Market – Key Players and Competitive Analysis Report

The competitive landscape of the gene therapy market is marked by a blend of global leaders and regional players striving to capture market share through innovation, strategic partnerships, and geographic expansion. Major players such as Abeona Therapeutic, Novartis AG, Spark Therapeutics LLC, Gilead Sciences Inc., Bristol Myers Squibb, Adverum Biotechnologies, Alnylam Pharmaceuticals, American Gene Technologies, Applied Genetic Technologies Corporation, Biogen, and Ultrageny dominate the market by leveraging their strong research and development (R&D) capabilities and vast distribution networks. These companies focus on product innovation to enhance efficiency, scalability, and reliability, addressing the growing demand for advanced automation solutions. Competitive strategies such as mergers and acquisitions, collaborations with tech firms, and expanding product portfolios are common approaches to enhance market positioning and meet the diverse demands of industries.

Sangamo Biosciences is a biotechnological company based in Brisbane that transforms advanced research into genomic therapeutics that improve patients' lives by employing novel technologies for gene therapy, genome editing, cell therapy, and gene therapy regulation. The company works on projects for uncommon diseases and develops genetic treatments for individuals suffering from severe illnesses using its in-depth scientific and patented zinc finger technology. Along with its novel technologies, Sangamo is conducting numerous clinical trials. Some of them are led by international pharmaceutical industry partners to assess the tolerability, efficacy, and safety of genomic therapies. The company believes in creating a fully owned genomic medicine platform, which would be financed through its partners with renowned biopharmaceutical companies.

Voyager Therapeutics is a gene therapy company dedicated to developing innovative treatments for severe central nervous system (CNS) disorders. The company estimates that over 200 million individuals worldwide suffer from brain diseases that can emerge at any stage of life. Believing in the transformative potential of gene therapy, Voyager is focused on advancing innovative solutions to address these critical neurological conditions. The company is actively developing proprietary AAV-based gene therapies, including TRACER capsid discovery technology, to enhance targeted and efficient gene delivery. Voyager collaborates with biopharmaceutical leaders and gene therapy experts to engineer novel capsids that enable the safe and reliable transfer of therapeutic gene payloads, with the goal of improving patient outcomes and changing lives.

List of Key Companies in Gene Therapy Market

Bluebird Bio
Bristol Myers Squibb
Gilead Sciences Inc
GlaxoSmithKline
Novartis AG
Sangamo Biosciences
Spark Therapeutics LLC
Ultragenyx
Voyager Therapeutics

Gene Therapy Industry Development

In January 2023, Voyager entered a strategic collaboration with Neurocrine Biosciences to develop gene therapies targeting neurological diseases, including a GBA1 gene therapy program for Parkinson's disease.

In May 2022, Voyager Therapeutics announced an option agreement with Novartis to target specific access to next-generation TRACER AAV capsids for gene therapy programs.

In May 2022, Ultragenyx acquired the global rights of AAV gene therapy from Abeona therapeutics, which is used to treat Sanfilippo syndrome type A (MPS IIIA).

Gene Therapy Market Segmentation

By Type Therapeutic Area Outlook (Revenue, USD Million, 2020–2034)

Autoimmune Disorders
Cardiovascular Diseases
Dermatological Disorders
Hematological Disorders
Metabolic Disorders
Muscle-Related Diseases
Oncological Disorders
Others

By Vector Type Outlook (Revenue, USD Million, 2020–2034)

Viral
Non-Viral

By Approach Outlook (Revenue, USD Million, 2020–2034)

Gene Augmentation
Oncolytic Viral Therapy
Immunotherapy
Other Approaches

By Route of Administration Outlook (Revenue, USD Million, 2020–2034)

Intraarticular
Intracerebellar
Intradermal
Intramuscular
Intratumoral
Intravenous
Intravesical
Intravitreal
Subretinal
Others

By Regional Outlook (Revenue, USD Million, 2020–2034)

North America
- US
- Canada
Europe
- Germany
- France
- UK
- Italy
- Spain
- Netherlands
- Russia
- Rest of Europe
Asia Pacific
- China
- Japan
- India
- Malaysia
- South Korea
- Indonesia
- Australia
- Rest of Asia Pacific
Middle East & Africa
- Saudi Arabia
- UAE
- Israel
- South Africa
- Rest of Middle East & Africa
Latin America
- Mexico
- Brazil
- Argentina
- Rest of Latin America

Gene Therapy Market Report Scope

Report Attributes	Details
Market Size Value in 2024	USD 2,251.50 million
Market Size Value in 2025	USD 2,657.00 million
Revenue Forecast by 2034	USD 27,250.20 million
CAGR	27.1% from 2025 to 2034
Base Year	2024
Historical Data	2020–2023
Forecast Period	2025–2034
Quantitative Units	Revenue in USD million and CAGR from 2025 to 2034
Report Coverage	Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends
Segments Covered	By Therapeutic Area By Vector Type By Approach By Route of Administration
Regional Scope	North America Europe Asia Pacific Latin America Middle East & Africa
Competitive Landscape	Gene Therapy Industry Trend Analysis (2024) Company Profiles/Industry participants profiling includes company overview, financial information, product/service benchmarking, and recent developments
Report Format	PDF + Excel
Customization	Report customization as per your requirements with respect to countries, regions, and segmentation.

FAQ's

1. What are the gene therapy market statistics?

• The global gene therapy market size was valued at USD 2,251.50 million in 2024 and is projected to grow to USD 27,250.20 million by 2034.

2. What is the growth rate of the gene therapy market value?

• The global market is projected to register a CAGR of 27.1% during the forecast period.

3. Which region dominated the gene therapy market share in 2024?

• North America dominated the market in 2024.

4. Who are the key players in the market?

• A few key players in the market are Voyager, Abeona Therapeutic, Novartis AG, Spark Therapeutics LLC, Gilead Sciences Inc., Bristol Myers Squibb, Adverum Biotechnologies, Alnylam Pharmaceuticals, American Gene Technologies, Applied Genetic Technologies Corporation, Biogen, and Ultragenyx.

5. Which segment, by therapeutic area, dominated the gene therapy market revenue share in 2024?

• The oncological disorders segment led the market share in 2024.

6. By vector type, which segment is anticipated to register a higher growth rate in the gene therapy market during 2025–2034?

• The viral segment is anticipated to register a higher growth rate during the forecast period.

Chapter 1.   Introduction
1.1   Report Description
1.1.1   Objectives of the Study
1.1.2   Market Scope
1.1.3   Assumptions
1.2   Stakeholders
Chapter 2.   Executive Summary
Chapter 3.   Research Methodology
3.1   Overview
3.1.1   Data Mining
3.2   Data Sources
3.2.1   Primary Sources
3.2.2   Secondary Sources
Chapter 4.   Gene Therapy Market Insights
4.1   Gene Therapy – Industry snapshot
4.1   Gene Therapy Market Dynamics
4.1.1   Drivers and Opportunities
4.1.1.1   Rising Approval and Investments in Gene Therapy Development
4.1.1.2 Growing Prevalence of Target Diseases
4.1.1.3 Growing Geriatric Population Base
4.1.2   Restraints and Challenges
4.1.2.1   Manufacturing and logistics challenges
4.1.2.2   High Procedure Costs and Presence of Ambiguous Regulatory Framework
4.1.2.3   Lack of Healthcare Infrastructure
4.2   Gene Therapy Market – Porter’s Five Forces
4.2.1   Bargaining Power of Suppliers (High)
4.2.2   Threats of New Entrants: (Low)
4.2.3   Bargaining Power of Buyers (Moderate)
4.2.4   Threat of Substitute (Low)
4.2.5   Rivalry among existing firms (High)
4.3   Gene Therapy Market – PEST Analysis
4.4   Covid-19 Impact Analysis & Industry Trends
Chapter 5.   Gene Therapy Market Assessment by Therapeutic Area
5.1   Introduction
5.2   Autoimmune Disorders
5.3   Cardiovascular Diseases
5.4   Dermatological Disorders
5.5   Hematological Disorders
5.6   Metabolic Disorders
5.7   Muscle-related Diseases
5.8   Oncological Disorders
5.9   Other Therapeutic Areas
Chapter 6.   Gene Therapy Market Assessment by Vector Type
6.1   Introduction
6.2   Viral
6.2.1   Retroviral vectors
6.2.1.1   Gamma-retroviral vectors
6.2.1.2   Lentiviral vectors
6.2.2   Adeno-associated virus vectors
6.2.3   Other viral vectors
6.3   Non-Viral
6.3.1   Oligonucleotides
6.3.2   Other non-viral vectors
Chapter 7.   Gene Therapy Market Assessment by Approach
7.1   Introduction
7.2   Gene Augmentation
7.1   Oncolytic Viral Therapy
7.2   Immunotherapy
7.3   Other Approaches
Chapter 8.   Gene Therapy Market Assessment by Route of Administration
8.1   Introduction
8.2   Intraarticular
8.3   Intracerebellar
8.4   Intradermal
8.5   Intramuscular
8.6   Intratumoral
8.7   Intravenous
8.8   Intravesical
8.9   Intravitreal
8.10   Subretinal
8.11   Others
Chapter 9.   Gene Therapy Market Assessment by Region
9.1   Introduction
9.2   Gene Therapy Market – North America
9.2.1   Gene Therapy Market – U.S.
9.2.2   Gene Therapy Market – Canada
9.3   Gene Therapy Market – Europe
9.3.1   Gene Therapy Market – Germany
9.3.2   Gene Therapy Market – UK
9.3.3   Gene Therapy Market – France
9.3.4   Gene Therapy Market – Italy
9.3.5   Gene Therapy Market – Spain
9.3.6   Gene Therapy Market – Netherlands
9.3.7   Gene Therapy Market – Austria
9.4   Gene Therapy Market – Asia Pacific
9.4.1   Gene Therapy Market – China
9.4.2   Gene Therapy Market – India
9.4.3   Gene Therapy Market – Japan
9.4.4   Gene Therapy Market – South Korea
9.5   Gene Therapy Market – Latin America
9.5.1   Gene Therapy Market – Brazil
9.5.2   Gene Therapy Market – Mexico
9.6   Gene Therapy Market – Middle East & Africa
9.6.1   Gene Therapy Market – Saudi Arabia
9.6.2   Gene Therapy Market – UAE
Chapter 10.   Competitive Landscape
10.1   Key Market Players: Categorization
10.2   Strategy Framework
10.3   Vendor Landscape
10.4   Strategies Categorization
10.4.1   Partnerships/Collaborations/Agreements
10.4.2   Expansions/Mergers/Acquisitions
10.4.3   Product Development/New Launch
Chapter 11.   Company Profiles
11.1   Sangamo Biosciences
11.1.1   Business Overview
11.1.2   Financial Snapshot
11.1.3   Products and Services
11.1.4   Recent Developments
11.2   Voyager Therapeutics
11.2.1   Business Overview
11.2.2   Financial Snapshot
11.2.3   Products and Services
11.2.4   Recent Developments
11.3   Ultragenyx
11.3.1   Business Overview
11.3.2   Financial Snapshot
11.3.3   Products and Services
11.3.4   Recent Developments
11.4   GlaxoSmithKline
11.4.1   Business Overview
11.4.2   Financial Snapshot
11.4.3   Products and Services
11.4.4   Recent Developments
11.5   Gilead Sciences Inc
11.5.1   Business Overview
11.5.2   Financial Snapshot
11.5.3   Products and Services
11.5.4   Recent Developments
11.6   Bristol Myers Squibb
11.6.1   Business Overview
11.6.2   Financial Snapshot
11.6.3   Products and Services
11.6.4   Recent Developments
11.7   Novartis AG
11.7.1   Business Overview
11.7.2   Financial Snapshot
11.7.3   Products and Services
11.7.4   Recent Developments
11.8   Spark Therapeutics LLC
11.8.1   Business Overview
11.8.2   Products and Services
11.8.3   Recent Developments
11.9   Bluebird Bio
11.9.1   Business Overview
11.9.2   Recent Developments
11.9.3   Products and Services
11.9.4   Recent Developments
List of Tables
Table 1   Global Gene Therapy Market, By Therapeutic Area, 2020–2034 (USD Million)
Table 1   Global Gene Therapy Market, by Autoimmune Disorders, 2020–2034 (USD Million)
Table 2   Global Gene Therapy Market, by Cardiovascular Diseases, 2020–2034 (USD Million)
Table 3   Global Gene Therapy Market, by Dermatological Disorders, 2020–2034 (USD Million)
Table 4   Global Gene Therapy Market, by Hematological Disorders, 2020–2034 (USD Million)
Table 5   Global Gene Therapy Market, by Metabolic Disorders, 2020–2034 (USD Million)
Table 6   Global Gene Therapy Market, by Muscle-related Diseases, 2020–2034 (USD Million)
Table 7   Global Gene Therapy Market, by Oncological Disorders, 2020–2034 (USD Million)
Table 8   Global Gene Therapy Market, by Other Therapeutic Areas, 2020–2034 (USD Million)
Table 9   Global Gene Therapy Market, By Vector Type, 2020–2034 (USD Million)
Table 10   Global Gene Therapy Market, by Viral, 2020–2034 (USD Million)
Table 11   Global Gene Therapy Market, by Retroviral vectors, 2020–2034 (USD Million)
Table 12   Global Gene Therapy Market, by Gamma-retroviral vectors, 2020–2034 (USD Million)
Table 13   Global Gene Therapy Market, by Lentiviral vectors, 2020–2034 (USD Million)
Table 14   Global Gene Therapy Market, by Adeno-associated virus vectors, 2020–2034 (USD Million)
Table 15   Global Gene Therapy Market, by Other viral vectors, 2020–2034 (USD Million)
Table 16   Global Gene Therapy Market, by Non-Viral, 2020–2034 (USD Million)
Table 17   Global Gene Therapy Market, by Oligonucleotides, 2020–2034 (USD Million)
Table 18   Global Gene Therapy Market, by Other non-viral vectors, 2020–2034 (USD Million)
Table 19   Global Gene Therapy Market, By Approach, 2020–2034 (USD Million)
Table 20   Global Gene Therapy Market, by Gene Augmentation, 2020–2034 (USD Million)
Table 21   Global Gene Therapy Market, by Oncolytic Viral Therapy, 2020–2034 (USD Million)
Table 22   Global Gene Therapy Market, by Immunotherapy, 2020–2034 (USD Million)
Table 23   Global Gene Therapy Market, by Other Approaches, 2020–2034 (USD Million)
Table 24   Global Gene Therapy Market, By Route of Administration, 2020–2034 (USD Million)
Table 25   Global Gene Therapy Market, by Intraarticular, 2020–2034 (USD Million)
Table 26   Global Gene Therapy Market, by Intracerebellar, 2020–2034 (USD Million)
Table 27   Global Gene Therapy Market, by Intradermal, 2020–2034 (USD Million)
Table 28   Global Gene Therapy Market, by Intramuscular, 2020–2034 (USD Million)
Table 29   Global Gene Therapy Market, by Intratumoral, 2020–2034 (USD Million)
Table 30   Global Gene Therapy Market, by Intravenous, 2020–2034 (USD Million)
Table 31   Global Gene Therapy Market, by Intravesical, 2020–2034 (USD Million)
Table 32   Global Gene Therapy Market, by Intravitreal, 2020–2034 (USD Million)
Table 33   Global Gene Therapy Market, by Subretinal, 2020–2034 (USD Million)
Table 34   Global Gene Therapy Market, by Others, 2020–2034 (USD Million)
Table 35   Gene Therapy Market Assessment, By Geography, 2020–2034 (USD Million)
Table 36   North America Gene Therapy Market, By Therapeutic Area, 2020–2034 (USD Million)
Table 37   North America Gene Therapy Market, By Vector Type, 2020–2034 (USD Million)
Table 38   North America Gene Therapy Market, By Viral Vector, 2020–2034 (USD Million)
Table 39   North America Gene Therapy Market, By Retroviral Vector, 2020–2034 (USD Million)
Table 40   North America Gene Therapy Market, By Non-viral vectors, 2020–2034 (USD Million)
Table 41   North America Gene Therapy Market, By Approach, 2020–2034 (USD Million)
Table 42   North America Gene Therapy Market, By Route of Administration, 2020–2034 (USD Million)
Table 43   U.S. Gene Therapy Market, By Therapeutic Area, 2020–2034 (USD Million)
Table 44   U.S. Gene Therapy Market, By Vector Type, 2020–2034 (USD Million)
Table 45   U.S. Gene Therapy Market, By Viral Vector, 2020–2034 (USD Million)
Table 46   U.S. Gene Therapy Market, By Retroviral vectors, 2020–2034 (USD Million)
Table 47   U.S. Gene Therapy Market, By Non-viral vectors, 2020–2034 (USD Million)
Table 48   U.S. Gene Therapy Market, By Approach, 2020–2034 (USD Million)
Table 49   U.S. Gene Therapy Market, By Route of Administration, 2020–2034 (USD Million)
Table 50   Canada Gene Therapy Market, By Therapeutic Area, 2020–2034 (USD Million)
Table 51   Canada Gene Therapy Market, By Vector Type, 2020–2034 (USD Million)
Table 52   Canada Gene Therapy Market, By Viral Vector, 2020–2034 (USD Million)
Table 53   Canada Gene Therapy Market, By Therapeutic Area, 2020–2034 (USD Million)
Table 54   Canada Gene Therapy Market, By Non-viral vectors, 2020–2034 (USD Million)
Table 55   Canada Gene Therapy Market, By Approach, 2020–2034 (USD Million)
Table 56   Canada Gene Therapy Market, By Route of Administration, 2020–2034 (USD Million)
Table 57   Europe Gene Therapy Market, By Therapeutic Area, 2020–2034 (USD Million)
Table 58   Europe Gene Therapy Market, By Vector Type, 2020–2034 (USD Million)
Table 59   Europe Gene Therapy Market, By Viral Vector, 2020–2034 (USD Million)
Table 60   Europe Gene Therapy Market, By Retroviral vectors, 2020–2034 (USD Million)
Table 61   Europe Gene Therapy Market, By Non-viral vectors, 2020–2034 (USD Million)
Table 62   Europe Gene Therapy Market, By Approach, 2020–2034 (USD Million)
Table 63   Europe Gene Therapy Market, By Route of Administration, 2020–2034 (USD Million)
Table 64   Germany Gene Therapy Market, By Therapeutic Area, 2020–2034 (USD Million)
Table 65   Germany Gene Therapy Market, By Vector Type, 2020–2034 (USD Million)
Table 66   Germany Gene Therapy Market, By Viral Vector, 2020–2034 (USD Million)
Table 67   Germany Gene Therapy Market, By Retroviral Vector, 2020–2034 (USD Million)
Table 68   Germany Gene Therapy Market, By Non-viral vectors, 2020–2034 (USD Million)
Table 69   Germany Gene Therapy Market, By Approach, 2020–2034 (USD Million)
Table 70   Germany Gene Therapy Market, By Route of Administration, 2020–2034 (USD Million)
Table 71   UK Gene Therapy Market, By Therapeutic Area, 2020–2034 (USD Million)
Table 72   UK Gene Therapy Market, By Vector Type, 2020–2034 (USD Million)
Table 73   UK Gene Therapy Market, By Viral Vector, 2020–2034 (USD Million)
Table 74   UK Gene Therapy Market, By Retroviral vectors, 2020–2034 (USD Million)
Table 75   UK Gene Therapy Market, By Non-viral vectors, 2020–2034 (USD Million)
Table 76   UK Gene Therapy Market, By Approach, 2020–2034 (USD Million)
Table 77   UK Gene Therapy Market, By Route of Administration, 2020–2034 (USD Million)
Table 78   France Gene Therapy Market, By Therapeutic Area, 2020–2034 (USD Million)
Table 79   France Gene Therapy Market, By Vector Type, 2020–2034 (USD Million)
Table 80   France Gene Therapy Market, By Viral Vector, 2020–2034 (USD Million)
Table 81   France Gene Therapy Market, By Therapeutic Area, 2020–2034 (USD Million)
Table 82   France Gene Therapy Market, By Non-viral vectors, 2020–2034 (USD Million)
Table 83   France Gene Therapy Market, By Approach, 2020–2034 (USD Million)
Table 84   France Gene Therapy Market, By Route of Administration, 2020–2034 (USD Million)
Table 85   Italy Gene Therapy Market, By Therapeutic Area, 2020–2034 (USD Million)
Table 86   Italy Gene Therapy Market, By Vector Type, 2020–2034 (USD Million)
Table 87   Italy Gene Therapy Market, By Viral Vector, 2020–2034 (USD Million)
Table 88   Italy Gene Therapy Market, By Retroviral vectors, 2020–2034 (USD Million)
Table 89   Italy Gene Therapy Market, By Non-viral vectors, 2020–2034 (USD Million)
Table 90   Italy Gene Therapy Market, By Approach, 2020–2034 (USD Million)
Table 91   Italy Gene Therapy Market, By Route of Administration, 2020–2034 (USD Million)
Table 92   Spain Gene Therapy Market, By Therapeutic Area, 2020–2034 (USD Million)
Table 93   Spain Gene Therapy Market, By Vector Type, 2020–2034 (USD Million)
Table 94   Spain Gene Therapy Market, By Viral Vector, 2020–2034 (USD Million)
Table 95   Spain Gene Therapy Market, By Retroviral Vector, 2020–2034 (USD Million)
Table 96   Spain Gene Therapy Market, By Non-viral vectors, 2020–2034 (USD Million)
Table 97   Spain Gene Therapy Market, By Approach, 2020–2034 (USD Million)
Table 98   Spain Gene Therapy Market, By Route of Administration, 2020–2034 (USD Million)
Table 99   Netherlands Gene Therapy Market, By Therapeutic Area, 2020–2034 (USD Million)
Table 100   Netherlands Gene Therapy Market, By Vector Type, 2020–2034 (USD Million)
Table 101   Netherlands Gene Therapy Market, By Viral Vector, 2020–2034 (USD Million)
Table 102   Netherlands Gene Therapy Market, By Retroviral vectors, 2020–2034 (USD Million)
Table 103   Netherlands Gene Therapy Market, By Non-viral vectors, 2020–2034 (USD Million)
Table 104   Netherlands Gene Therapy Market, By Approach, 2020–2034 (USD Million)
Table 105   Netherlands Gene Therapy Market, By Route of Administration, 2020–2034 (USD Million)
Table 106   Austria Gene Therapy Market, By Therapeutic Area, 2020–2034 (USD Million)
Table 107   Austria Gene Therapy Market, By Vector Type, 2020–2034 (USD Million)
Table 108   Austria Gene Therapy Market, By Viral Vector, 2020–2034 (USD Million)
Table 109   Austria Gene Therapy Market, By Therapeutic Area, 2020–2034 (USD Million)
Table 110   Austria Gene Therapy Market, By Non-viral vectors, 2020–2034 (USD Million)
Table 111   Austria Gene Therapy Market, By Approach, 2020–2034 (USD Million)
Table 112   Austria Gene Therapy Market, By Route of Administration, 2020–2034 (USD Million)
Table 113   Asia Pacific Gene Therapy Market, By Therapeutic Area, 2020–2034 (USD Million)
Table 114   Asia Pacific Gene Therapy Market, By Vector Type, 2020–2034 (USD Million)
Table 115   Asia Pacific Gene Therapy Market, By Viral Vector, 2020–2034 (USD Million)
Table 116   Asia Pacific Gene Therapy Market, By Retroviral vectors, 2020–2034 (USD Million)
Table 117   Asia Pacific Gene Therapy Market, By Non-viral vectors, 2020–2034 (USD Million)
Table 118   Asia Pacific Gene Therapy Market, By Approach, 2020–2034 (USD Million)
Table 119   Asia Pacific Gene Therapy Market, By Route of Administration, 2020–2034 (USD Million)
Table 120   China Gene Therapy Market, By Therapeutic Area, 2020–2034 (USD Million)
Table 121   China Gene Therapy Market, By Vector Type, 2020–2034 (USD Million)
Table 122   China Gene Therapy Market, By Viral Vector, 2020–2034 (USD Million)
Table 123   China Gene Therapy Market, By Retroviral Vector, 2020–2034 (USD Million)
Table 124   China Gene Therapy Market, By Non-viral vectors, 2020–2034 (USD Million)
Table 125   China Gene Therapy Market, By Approach, 2020–2034 (USD Million)
Table 126   China Gene Therapy Market, By Route of Administration, 2020–2034 (USD Million)
Table 127   India Gene Therapy Market, By Therapeutic Area, 2020–2034 (USD Million)
Table 128   India Gene Therapy Market, By Vector Type, 2020–2034 (USD Million)
Table 129   India Gene Therapy Market, By Viral Vector, 2020–2034 (USD Million)
Table 130   India Gene Therapy Market, By Retroviral vectors, 2020–2034 (USD Million)
Table 131   India Gene Therapy Market, By Non-viral vectors, 2020–2034 (USD Million)
Table 132   India Gene Therapy Market, By Approach, 2020–2034 (USD Million)
Table 133   India Gene Therapy Market, By Route of Administration, 2020–2034 (USD Million)
Table 134   Japan Gene Therapy Market, By Therapeutic Area, 2020–2034 (USD Million)
Table 135   Japan Gene Therapy Market, By Vector Type, 2020–2034 (USD Million)
Table 136   Japan Gene Therapy Market, By Viral Vector, 2020–2034 (USD Million)
Table 137   Japan Gene Therapy Market, By Therapeutic Area, 2020–2034 (USD Million)
Table 138   Japan Gene Therapy Market, By Non-viral vectors, 2020–2034 (USD Million)
Table 139   Japan Gene Therapy Market, By Approach, 2020–2034 (USD Million)
Table 140   Japan Gene Therapy Market, By Route of Administration, 2020–2034 (USD Million)
Table 141   South Korea Gene Therapy Market, By Therapeutic Area, 2020–2034 (USD Million)
Table 142   South Korea Gene Therapy Market, By Vector Type, 2020–2034 (USD Million)
Table 143   South Korea Gene Therapy Market, By Viral Vector, 2020–2034 (USD Million)
Table 144   South Korea Gene Therapy Market, By Retroviral vectors, 2020–2034 (USD Million)
Table 145   South Korea Gene Therapy Market, By Non-viral vectors, 2020–2034 (USD Million)
Table 146   South Korea Gene Therapy Market, By Approach, 2020–2034 (USD Million)
Table 147   South Korea Gene Therapy Market, By Route of Administration, 2020–2034 (USD Million)
Table 148   Latin America Gene Therapy Market, By Therapeutic Area, 2020–2034 (USD Million)
Table 149   Latin America Gene Therapy Market, By Vector Type, 2020–2034 (USD Million)
Table 150   Latin America Gene Therapy Market, By Viral Vector, 2020–2034 (USD Million)
Table 151   Latin America Gene Therapy Market, By Therapeutic Area, 2020–2034 (USD Million)
Table 152   Latin America Gene Therapy Market, By Non-viral vectors, 2020–2034 (USD Million)
Table 153   Latin America Gene Therapy Market, By Approach, 2020–2034 (USD Million)
Table 154   Latin America Gene Therapy Market, By Route of Administration, 2020–2034 (USD Million)
Table 155   Brazil Gene Therapy Market, By Therapeutic Area, 2020–2034 (USD Million)
Table 156   Brazil Gene Therapy Market, By Vector Type, 2020–2034 (USD Million)
Table 157   Brazil Gene Therapy Market, By Viral Vector, 2020–2034 (USD Million)
Table 158   Brazil Gene Therapy Market, By Retroviral vectors, 2020–2034 (USD Million)
Table 159   Brazil Gene Therapy Market, By Non-viral vectors, 2020–2034 (USD Million)
Table 160   Brazil Gene Therapy Market, By Approach, 2020–2034 (USD Million)
Table 161   Brazil Gene Therapy Market, By Route of Administration, 2020–2034 (USD Million)
Table 162   Mexico Gene Therapy Market, By Therapeutic Area, 2020–2034 (USD Million)
Table 163   Mexico Gene Therapy Market, By Vector Type, 2020–2034 (USD Million)
Table 164   Mexico Gene Therapy Market, By Viral Vector, 2020–2034 (USD Million)
Table 165   Mexico Gene Therapy Market, By Retroviral Vector, 2020–2034 (USD Million)
Table 166   Mexico Gene Therapy Market, By Non-viral vectors, 2020–2034 (USD Million)
Table 167   Mexico Gene Therapy Market, By Approach, 2020–2034 (USD Million)
Table 168   Mexico Gene Therapy Market, By Route of Administration, 2020–2034 (USD Million)
Table 169   Middle East & Africa Gene Therapy Market, By Therapeutic Area, 2020–2034 (USD Million)
Table 170   Middle East & Africa Gene Therapy Market, By Vector Type, 2020–2034 (USD Million)
Table 171   Middle East & Africa Gene Therapy Market, By Viral Vector, 2020–2034 (USD Million)
Table 172   Middle East & Africa Gene Therapy Market, By Retroviral vectors, 2020–2034 (USD Million)
Table 173   Middle East & Africa Gene Therapy Market, By Non-viral vectors, 2020–2034 (USD Million)
Table 174   Middle East & Africa Gene Therapy Market, By Approach, 2020–2034 (USD Million)
Table 175   Middle East & Africa Gene Therapy Market, By Route of Administration, 2020–2034 (USD Million)
Table 176   Saudi Arabia Gene Therapy Market, By Therapeutic Area, 2020–2034 (USD Million)
Table 177   Saudi Arabia Gene Therapy Market, By Vector Type, 2020–2034 (USD Million)
Table 178   Saudi Arabia Gene Therapy Market, By Viral Vector, 2020–2034 (USD Million)
Table 179   Saudi Arabia Gene Therapy Market, By Therapeutic Area, 2020–2034 (USD Million)
Table 180   Saudi Arabia Gene Therapy Market, By Non-viral vectors, 2020–2034 (USD Million)
Table 181   Saudi Arabia Gene Therapy Market, By Approach, 2020–2034 (USD Million)
Table 182   Saudi Arabia Gene Therapy Market, By Route of Administration, 2020–2034 (USD Million)
Table 183   UAE Gene Therapy Market, By Therapeutic Area, 2020–2034 (USD Million)
Table 184   UAE Gene Therapy Market, By Vector Type, 2020–2034 (USD Million)
Table 185   UAE Gene Therapy Market, By Viral Vector, 2020–2034 (USD Million)
Table 186   UAE Gene Therapy Market, By Retroviral vectors, 2020–2034 (USD Million)
Table 187   UAE Gene Therapy Market, By Non-viral vectors, 2020–2034 (USD Million)
Table 188   UAE Gene Therapy Market, By Approach, 2020–2034 (USD Million)
Table 189   UAE Gene Therapy Market, By Route of Administration, 2020–2034 (USD Million)
List of Figures
Figure 1.   Executive Summary
Figure 2.   Research Methodology: Top Down & Bottom-Up Approach
Figure 3.   Market by Geography, 2020–2034 (USD Million)
Figure 6.   Porter’s Five Forces
Figure 7.   PEST Analysis
Figure 8.   Market by Therapeutic Area
Figure 9.   Global Gene Therapy Market, By Therapeutic Area, 2024 & 2034 (USD Million)
Figure 10.   Market by Vector Type
Figure 11.   Global Gene Therapy Market, By Vector Type, 2024 & 2034 (USD Million)
Figure 12.   Market by Approach
Figure 13.   Global Gene Therapy Market, By Approach, 2024 & 2034 (USD Million)
Figure 14.   Market by Route of Administration
Figure 15.   Global Gene Therapy Market, By Route of Administration, 2024 & 2034 (USD Million)
Figure 16.   Gene Therapy Market Assessment, By Geography, 2024 & 2034 (USD Million)

Report Scope

Gene Therapy Market, Type Therapeutic Area Outlook (Revenue - USD Million, 2020-2034)

Autoimmune Disorders
Cardiovascular Diseases
Dermatological Disorders
Hematological Disorders
Metabolic Disorders
Muscle-Related Diseases
Oncological Disorders
Others

Gene Therapy Market, Vector Type Outlook (Revenue - USD Million, 2020-2034)

Viral
Non-Viral

Gene Therapy Market, Approach Outlook (Revenue - USD Million, 2020-2034)

Gene Augmentation
Oncolytic Viral Therapy
Immunotherapy
Other Approaches

Gene Therapy Market, Route of Administration Outlook (Revenue - USD Million, 2020-2034)

Intraarticular
Intracerebellar
Intradermal
Intramuscular
Intratumoral
Intravenous
Intravesical
Intravitreal
Subretinal
Others

Gene Therapy Market, Regional Outlook (Revenue - USD Million, 2020-2034)

North America
- Type Therapeutic Area Outlook
  - Autoimmune Disorders
  - Cardiovascular Diseases
  - Dermatological Disorders
  - Hematological Disorders
  - Metabolic Disorders
  - Muscle-Related Diseases
  - Oncological Disorders
  - Others
- Vector Type Outlook
  - Viral
  - Non-Viral
- Approach Outlook
  - Gene Augmentation
  - Oncolytic Viral Therapy
  - Immunotherapy
  - Other Approaches
- Route of Administration Outlook
  - Intraarticular
  - Intracerebellar
  - Intradermal
  - Intramuscular
  - Intratumoral
  - Intravenous
  - Intravesical
  - Intravitreal
  - Subretinal
  - Others
Europe
- Type Therapeutic Area Outlook
  - Autoimmune Disorders
  - Cardiovascular Diseases
  - Dermatological Disorders
  - Hematological Disorders
  - Metabolic Disorders
  - Muscle-Related Diseases
  - Oncological Disorders
  - Others
- Vector Type Outlook
  - Viral
  - Non-Viral
- Approach Outlook
  - Gene Augmentation
  - Oncolytic Viral Therapy
  - Immunotherapy
  - Other Approaches
- Route of Administration Outlook
  - Intraarticular
  - Intracerebellar
  - Intradermal
  - Intramuscular
  - Intratumoral
  - Intravenous
  - Intravesical
  - Intravitreal
  - Subretinal
  - Others
Asia Pacific
- Type Therapeutic Area Outlook
  - Autoimmune Disorders
  - Cardiovascular Diseases
  - Dermatological Disorders
  - Hematological Disorders
  - Metabolic Disorders
  - Muscle-Related Diseases
  - Oncological Disorders
  - Others
- Vector Type Outlook
  - Viral
  - Non-Viral
- Approach Outlook
  - Gene Augmentation
  - Oncolytic Viral Therapy
  - Immunotherapy
  - Other Approaches
- Route of Administration Outlook
  - Intraarticular
  - Intracerebellar
  - Intradermal
  - Intramuscular
  - Intratumoral
  - Intravenous
  - Intravesical
  - Intravitreal
  - Subretinal
  - Others
Latin America
- Type Therapeutic Area Outlook
  - Autoimmune Disorders
  - Cardiovascular Diseases
  - Dermatological Disorders
  - Hematological Disorders
  - Metabolic Disorders
  - Muscle-Related Diseases
  - Oncological Disorders
  - Others
- Vector Type Outlook
  - Viral
  - Non-Viral
- Approach Outlook
  - Gene Augmentation
  - Oncolytic Viral Therapy
  - Immunotherapy
  - Other Approaches
- Route of Administration Outlook
  - Intraarticular
  - Intracerebellar
  - Intradermal
  - Intramuscular
  - Intratumoral
  - Intravenous
  - Intravesical
  - Intravitreal
  - Subretinal
  - Others
Middle East & Africa
- Type Therapeutic Area Outlook
  - Autoimmune Disorders
  - Cardiovascular Diseases
  - Dermatological Disorders
  - Hematological Disorders
  - Metabolic Disorders
  - Muscle-Related Diseases
  - Oncological Disorders
  - Others
- Vector Type Outlook
  - Viral
  - Non-Viral
- Approach Outlook
  - Gene Augmentation
  - Oncolytic Viral Therapy
  - Immunotherapy
  - Other Approaches
- Route of Administration Outlook
  - Intraarticular
  - Intracerebellar
  - Intradermal
  - Intramuscular
  - Intratumoral
  - Intravenous
  - Intravesical
  - Intravitreal
  - Subretinal
  - Others

Qualitative Analysis

Industry overview
- Industry trends
- Market drivers and restraints
- Market size
- Growth prospects
- Porter’s analysis
- PESTEL Analysis
- Value Chain Analysis
- Key market opportunities prioritized
Competitive landscape
- Overview
- Financials
- Route of Administration benchmarking
- Latest strategic developments
- Price Trend Analysis

Quantitative Analysis

Market size, estimates, and forecasts from 2020-2034
Market size and revenue estimates for Route of Administration from 2034
Market revenue estimates for Type Therapeutic Area from 2034
Market revenue estimates for Vector Type from 2034
Market revenue estimates for Approach from 2034
Regional market size and forecast from 2034
Company financials

Request For Customization

Please fill out the form to request a customized copy of the research report.

Select Your Customizing Purchase Options
Segmentation Analysis Industry Outlook Competitive Analysis

We take great pride in "Delivering game-changing business opportunities reports with report customizations", so please don't hesitate to share with us your unique interests and business difficulties in much more detail.

By using this form you agree with the storage and handling of your data by this website.

This website is secure and your personal details are safe. Privacy Policy

Gene Therapy Market Opportunity, Trends, Industry Analysis Report, 2025 - 2034

What's Included in Full Report?

Request Sample Report